戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ging from zero (total occlusion) to 8 (fully patent).
2 arch articles (80%) link forward to a future patent.
3 d, leaving the large vessels of the fibroids patent.
4 ral ossification, while other sutures remain patent.
5 intervening penetrating vessels were acutely patent.
6 s, indicating that the periplasmic cavity is patent.
7  a grant and its propensity to be cited by a patent.
8 s well as so-called prophetic compounds from patents.
9 d disposition data and bioactivity data from patents.
10 impact publications, and 14% fewer follow-on patents.
11  Office may hear new challenges to stem cell patents.
12 wondered how genes were ever the subjects of patents.
13 he data are gathered from the literature and patents.
14 rate articles that are subsequently cited by patents.
15 n lymph node biopsies of follicular lymphoma patents.
16 ased on information in scientific papers and patents.
17  to control blood glucose levels in diabetic patents.
18 om scientific articles and, increasingly, US patents.
19 Food and Drug Administration approval and by patents.
20 action roles and yields, from pharmaceutical patents.
21 erformed within 3 months of diagnosis in 561 patents.
22 st time, that isolated human genes cannot be patented.
23 n public research investments and subsequent patenting.
24                   Eligible patients from the PATENT-1 study entered the PATENT-2 open-label extension
25 patients from the PATENT-1 study entered the PATENT-2 open-label extension, which will continue until
26 rial hypertension receiving riociguat in the PATENT-2 study.
27                         396 patients entered PATENT-2, of whom 197 patients were receiving riociguat
28  efficacy data from the final data cutoff of PATENT-2, where most patients had received at least 2 ye
29              Riociguat was well tolerated in PATENT-2.
30 eal-world networks, including 3.7 million US patents, 575,000 physics articles from the arXiv preprin
31                              Similarly, most patents (61%) link backward to a prior research article.
32 n level variables (contagious disease rates, patenting activity, economic productivity and crime) wit
33 ary circulation observed at surgery remained patent after plication.
34 usculature maintaining the architecture of a patent airway conduit and abdominal wall and internal in
35 -inflation upon surfacing, while maintaining patent airways.
36                                        These patents, along with other biological patents, generated
37 nimals survive the 14-day study period, with patent and functional grafts, and gain significantly mor
38 progression rates were then compared between patent and occluded vessels for each vessel type with Fi
39 nstrates the utility of publically available patent and publication data to quantify innovations with
40 hy-Smith America Invents Act (AIA), the U.S. Patent and Trademark Office may hear new challenges to s
41 substantial and fruitful connections between patenting and prior scientific inquiry.
42          The initial search retrieved 52,046 patents and 1,801,075 publications.
43                    We study 4.8 million U.S. patents and 32 million research articles to determine th
44 towards the daily use, analysing the various patents and applications reported to date.
45 st prices are issues of regulatory approval, patents and intellectual property, assessment of value a
46 ary text input (e.g. scholarly publications, patents and medical records) in multiple formats (e.g. B
47                                              Patents and publications (1981-2011) were evaluated usin
48 is study were to assess the applicability of patents and publications as metrics of surgical technolo
49 enzyme immobilization have been described in patents and publications, relatively few processes emplo
50 evaluate the historical relationship between patents and publications; develop a methodology that can
51 sment study based mainly on information from patents and scientific articles, enabling prospective li
52 ly multiplying number of research papers and patents and the broadening range of chemical, medical, e
53             Our analysis uses 1.8 million US patents and their citation properties to map the innovat
54                          All BVS were widely patent, and binary restenosis rate was 2% (the only rest
55  the history of tenure in the United States, patents, and licensing at universities, the current stat
56 ions, there is a steady increase in costs of patented anticancer agents over time.
57 tococcal meningitis relies on three old, off-patent antifungal drugs: amphotericin B deoxycholate, fl
58  the IMA ostium and the number of additional patent aortic side branches are associated with the deve
59  IMA type II endoleak had significantly more patent aortic side branches before EVAR than did patient
60 the IMA ostium, and the number of additional patent aortic side branches from the aneurysm sac.
61 s, the bulk of the effect of NIH research on patenting appears to be indirect.
62 s described in the primary literature and in patent applications.
63 e, open and timely set of annotated compound-patent associations, complemented with sophisticated com
64 bleeding was reported and the shunt remained patent at a 3-year follow-up.
65 is a pressing need shared by researchers and patent attorneys from different chemical disciplines.
66 label propagation such as labeling blogs and patents based on their citation networks.
67 35%), antibiotics (46%), chlorhexidine (8%), patent blue dye (8%) and others (8%).
68              Tumor perfusion was assessed by Patent blue staining.
69 ne (E127), Red 2G (E128), Allura Red (E129), Patent Blue V (E131), Indigo Carmine (E132), Brilliant B
70 ully patent, minimal, or no reflux; (b) >50% patent but some reflux; (c) some patency but >50% reflux
71 ferent reaction types used in pharmaceutical patents but a trend toward lower median yield for some o
72 Although policy-makers often focus on direct patenting by academic scientists, the bulk of the effect
73                              All cases had a patent canalicular system as demonstrated by syringing a
74 n = 10) required a Lester-Jones tube despite patent canaliculi, with a success rate of 90%.
75 analostomy would induce apical flow from the patent cochlear aqueduct to the canalostomy due to influ
76 rgeon" OR "surgical" OR "surgery." Resulting patent codes were grouped into technology clusters.
77                       No association between patent collateral circulation and favorable outcome was
78 ngi establish NSC319726 as a repurposed, off-patent compound that has potential antifungal activity.
79 tional cardiologist then measured FFR in all patent coronary arteries of stentable diameter (>/=2.25
80                 In addition, publication and patent counts were closely correlated in areas of techno
81 l US performed three weeks later confirmed a patent covered stent and complete aneurysmal exclusion.
82 procedure, showed an excluded aneurysm and a patent covered stent.
83 BMP10 that correlated with the presence of a patent DA.
84 ormation from different sources (literature, patent databases) and novel sequence data to identify un
85                                   Electronic patenting databases and the MEDLINE database were search
86                 The US share of life science patents declined from 57% (1981) to 51% (2011), as did t
87 find that about 10% of NIH grants generate a patent directly but 30% generate articles that are subse
88 t cases, and discuss the future of stem cell patent disputes.
89 bilities against the compound repository and patent document corpus; given the wealth of knowledge hi
90 pus; given the wealth of knowledge hidden in patent documents, analysis of SureChEMBL data has immedi
91 rom the full text, images and attachments of patent documents.
92  million compounds extracted from 14 million patent documents.
93 nctionalization for the rapid synthesis of a patented drug candidate.
94 or AML, we screened a library of on- and off-patent drugs and identified the antimalarial agent meflo
95 ts of drug research, including resources for patented drugs, their side effects, withdrawn drugs, and
96 7, 47%), atrial septal defects (20/47, 43%), patent ductus arteriosus (16/47, 34%), persistent left s
97 ds ratio [AOR], 0.81; 95% CI, 0.67-0.98) and patent ductus arteriosus (AOR, 0.74; 95% CI, 0.62-0.89).
98 consensus for the screening and treatment of patent ductus arteriosus (PDA) in extremely preterm infa
99                                 Nonsyndromic patent ductus arteriosus (PDA) is a common congenital he
100                                              Patent ductus arteriosus (PDA) is associated with increa
101        Observational studies have associated patent ductus arteriosus (PDA) ligation among preterm in
102                                              Patent ductus arteriosus (PDA) poses a diagnostic and th
103 od flow may undergo palliation with either a patent ductus arteriosus (PDA) stent or a modified Blalo
104  Only one atrial septal defect (ASD) and two patent ductus arteriosus (PDA) were missed by DSCT.
105 ve (BAV), coarctation of the aorta (CoA) and patent ductus arteriosus (PDA).
106 trial septal defect (ASD); device closure of patent ductus arteriosus (PDA); pulmonary valvuloplasty;
107 tal defect (aORs ranging from 1.29 to 2.17), patent ductus arteriosus [aORs = 1.54, 1.63; 95% confide
108                                              Patent ductus arteriosus and coarctation of aorta occurr
109 11 (c.4599+1delG) was identified in familial patent ductus arteriosus and found to disrupt normal spl
110                                              Patent ductus arteriosus ligation among preterm neonates
111 tricular leukomalacia, chronic lung disease, patent ductus arteriosus requiring surgery, retinopathy
112  treated cases regardless of whether preterm patent ductus arteriosus was included.
113 f infants who required surgical closure of a patent ductus arteriosus was lower in the budesonide gro
114 al CHD, 4 with atrial septal defects, 2 with patent ductus arteriosus, 2 with tetralogy of Fallot, an
115   A concomitant cardiac lesion, for example, patent ductus arteriosus, and aortic cross-clamp time we
116 facial dysmorphology, osteochondrodysplasia, patent ductus arteriosus, cardiomegaly, pericardial effu
117 cts, persistent left superior vena cava, and patent ductus arteriosus, were present in 32% of patient
118 s of death or bronchopulmonary dysplasia and patent ductus arteriosus.
119 unts, H-type portal-caval, portohepatic, and patent ductus venosus patients had a successful 1-stage
120  to include or exclude all types of DNA from patent eligibility could impact future incentives for ge
121                FFR was measured in all major patent epicardial coronary arteries with a visual stenos
122 -33) months, all venous reconstructions were patent except for 1 tubular graft (97%).
123 ding on third-party payer issues and product patent expiration dates.
124 ding on third-party payer issues and product patent expiration dates.
125 g reduced efficiency, stagnant success rate, patent expirations for key drugs, fierce price competiti
126 educed efficiency, declining innovation, key patent expirations, fierce price competition from generi
127 These are associated with not only expanding patent extraction but also increasingly large vendor col
128 were 18 to 40 years of age, had at least one patent fallopian tube and a normal uterine cavity, and h
129 omen 18 to 40 years of age with at least one patent fallopian tube were randomly assigned to ovarian
130 of it in Anglo and European regions, whereas patents' families/friends were the most common source in
131 fusion had no effect on the EPR in rats with patent femoral arteries (n = 9).
132  infusion on the pressor reflex in rats with patent femoral arteries.
133           Immune modulation is a hallmark of patent filarial infection, including suppression of anti
134  the new law affects challenges to stem cell patents, focusing on two recent cases, and discuss the f
135  the course of in vitro culture and remained patent for 3 days after orthotopic transplantation in ra
136 ld-type controls, and their sutures remained patent for a longer period of time.
137 ovenous shunts and implanted in pigs, remain patent for at least 8 h without anticoagulation.
138 potential anticancer drug tranilast has been patented for treating Alzheimer's disease (AD), in which
139 n of oxetane derivatives appearing in recent patents for medicinal chemistry applications.
140                                          The patents for the first approved treatments for relapsing-
141 ned patients 18 to 60 years of age who had a patent foramen ovale (PFO) and had had a cryptogenic isc
142 dary prevention of embolism in patients with patent foramen ovale (PFO) and otherwise unexplained isc
143                                              Patent foramen ovale (PFO) can be detected in up to 43%
144                                    Trials of patent foramen ovale (PFO) closure to prevent recurrent
145                                              Patent foramen ovale (PFO) has been associated with migr
146                 The efficacy of closure of a patent foramen ovale (PFO) in the prevention of recurren
147                                              Patent foramen ovale (PFO) is associated with cryptogeni
148                                            A patent foramen ovale (PFO) may permit arterial embolizat
149 ive effectiveness of percutaneous closure of patent foramen ovale (PFO) plus medical therapy versus m
150 o right-to-left shunted blood flow through a patent foramen ovale (PFO) would not be cooled.
151 udy was to evaluate the relationship between patent foramen ovale (PFO), ischemic stroke, and subclin
152                              Patients with a patent foramen ovale and ischemic stroke, transient isch
153 ion of cryptogenic embolism in patients with patent foramen ovale are administration of antithromboti
154 Initial results using these tools to perform patent foramen ovale closure are described.
155     As a demonstration of both technologies, patent foramen ovale creation and closure was performed
156                                 Closure of a patent foramen ovale for secondary prevention of cryptog
157 ificant benefit associated with closure of a patent foramen ovale in adults who had had a cryptogenic
158                         Whether closure of a patent foramen ovale is effective in the prevention of r
159 rocedure (11%), aortic valve procedure (9%), patent foramen ovale or atrial septal defect closure (23
160                         Whether closure of a patent foramen ovale reduces the risk of recurrence of i
161                     In the second group, the patent foramen ovale was not successfully created in 1 a
162  randomly assigned to undergo closure of the patent foramen ovale with the Amplatzer PFO Occluder or
163 occurred in 47% (including 17% with isolated patent foramen ovale), and 11% had undetermined stroke e
164 uding occult paroxysmal atrial fibrillation, patent foramen ovale, aortic arch atherosclerosis, atria
165      When pulmonary embolism coexists with a patent foramen ovale, increased pressure in the right at
166 , to medical therapy alone or closure of the patent foramen ovale.
167 c medications or percutaneous closure of the patent foramen ovale.
168 DVT and paradoxical embolism due to existing patent foramen ovale.
169                                          All patent foramen ovales were completely closed in the firs
170 opulation, harbor a third of infections with patent gametocytes between May and August, when transmis
171   These patents, along with other biological patents, generated substantial social and political crit
172 eloped during a time when it was possible to patent genes.
173   A survey of the claims of antibody-related patents granted by the European Patent Office and a revi
174 cantly greater in the early ST compared with patent group (28% vs.11%, p < 0.001; 27% vs. 15% p = 0.0
175 n of this preexisting network structure with patent growth in upstream technology fields has strong p
176                                          All patents had fasting blood tests and anthropometric measu
177 hin the ablation zone (P = .02) but not with patent hepatic (P = .57) or portal (P = .14) veins.
178 ion rates were significantly correlated with patent hepatic arteries within the ablation zone (P = .0
179 t of 8 patients (75%) were asymptomatic with patent hepatic artery, which was confirmed by multislice
180     It requires no antibody and exploits the patented homogeneous time-resolved fluorescence (HTRF) t
181                       The RA was found to be patent in 24 cases (84.8% patency).
182 P2 KO arteries grafted into WT mice remained patent in vivo.
183 imately successful campaign to overturn gene patents in court.
184                        During early healing, patents in the azithromycin group exhibited a significan
185                        The top 10 most-cited patents in the field were dominated by 2 private entitie
186                         Patients with ER and patent index artery at 24 hours on CTA were labeled as h
187 h (Wuchereria bancrofti) infection such that patent infection altered the frequency and distribution
188 s highly infectious sporozoites that produce patent infection in mice that are exposed to the bites o
189 e mutant was associated with higher risks of patent infection in peripheral blood (adjusted prevalenc
190                           The association of patent infections at enrollment with low birth weight su
191       The tool identified both prepatent and patent infections using Schistosoma japonicum DNA isolat
192 ges in mean monthly costs for a cohort of 24 patented, injectable anticancer drugs that were approved
193 entation of medical research, the process of patenting intellectual property, and its potential impac
194  eyes had ischemic nonfunctioning blebs with patent internal ostia and underwent Nd:YAG LGP, followed
195 ermine the minimum citation distance between patented inventions and prior scientific advances.
196  of preparation, physicochemical properties, patented inventions and recent advances of these micelle
197 ripheral anterior chamber in the presence of patent iridotomy, with intraocular pressure (IOP) of 22
198        Leaving science to pursue a career in patent law requires a considerable investment of time an
199 e number of former scientists now practicing patent law shows that it can be done.
200 earchers (and patent offices) began to apply patent-law logic to genes themselves.
201 frequent in thrombosed lesions compared with patent lesions (70% vs. 43%, p = 0.045) and maximal unde
202 s significantly greater in thrombosed versus patent lesions.
203 to screen and characterize FDA-approved, off-patent library drugs for anti-Mycobacterium tuberculosis
204 sities should expand their criteria to treat patents, licensing, and commercialization activity by fa
205                                Using data on patents linked to U.S. National Institutes of Health (NI
206              The data are extracted from the patent literature according to an automated text and ima
207  KDMs, KDM2-7), focusing on the academic and patent literature from 2014 to date.
208 ents for the treatment of IPF along with the patent literature from the past 10 years.
209 a quinoline series recently disclosed in the patent literature into a chemotype previously used for t
210 c modulators disclosed in the scientific and patent literature.
211 cements, with a focus on both scientific and patent literature.
212 ratory, and the other is a compound from the patent literature.
213 gonists and summarizes the peer reviewed and patented literature.
214  these instances have been central issues in patent litigations.
215 h self-expandable metal stents (SEMS) remain patent longer than plastic stents, they are more expensi
216 ccluded, significantly stenosed (>/=50%), or patent (&lt;50% stenosis).
217 ta-catenin at the plasma membrane, induced a patent lumen in CRC spheroids, and slowed CRC cell invas
218  and stabilization of endothelial tubes with patent lumens is vital during vertebrate development.
219 stal extension of both the apical border and patent lumens.
220        Approximately 256 traditional Chinese patent medicines, containing Aristolochiaceous materials
221 were performed for relevant clinical trials, patents, meeting abstracts, and awards of NIH funding.
222 NAs) with potential utility as biomarkers of patent (mf (+) ) L. loa infection.
223 rimal syringing and categorized as (a) fully patent, minimal, or no reflux; (b) >50% patent but some
224 n-Friendly (GF) technology (Italian priority patent n degrees 102015000084813 filed on 17th December
225 mors we noted the emergence of CD31-negative patent neovessels and a concomitant loss of tumor homing
226 try level: the global trade network, and the patent network in different technological domains.
227 stration of numerous cell types and leads to patent, nonleaky, properly organized, and functional nas
228 tool extracting strain related publications, patents, nucleotide sequences and genome information fro
229                                     Once the patent of a brand-name drug expires, generic drugs are c
230 n, CTDs, and their derived dioxins since the patent of triclosan in 1964.
231 ived from triclosan are present prior to the patent of triclosan, suggesting a secondary source.
232 body-related patents granted by the European Patent Office and a review of the type and scope of prod
233  sequence came to fruition, researchers (and patent offices) began to apply patent-law logic to genes
234 ad evidence of a patent ostium and 100% were patent on lacrimal irrigation.
235              Myriad Genetics, a company with patents on BRCA1 and BRCA2, two genes critical to assess
236 ogy v Myriad Genetics, Inc seeks to overturn patents on isolated genes.
237 ity and the University of California to seek patents on the technology that Boyer and I had invented,
238 ility and outcomes of retrograde CTO PCI via patent or occluded saphenous vein graft.
239 ly, all coronary bypass grafts were rated as patent or occluded.
240 n within a cohort of commonly prescribed off-patent oral antibiotics.
241                     This inexpensive and off-patent oral medication is a promising adjunctive antifun
242  89% of the cases (n = 58) had evidence of a patent ostium and 100% were patent on lacrimal irrigatio
243 es, 127 (98.5%) had endoscopic evidence of a patent ostium with a positive endoscopic dye test at the
244 new data to track publication, citation, and patenting outcomes associated with more than 130,000 res
245  reactions and molecules retrieved from U.S. patents over the past 40 years (1976-2015).
246 preterm labour was also more common in these patents (p < 0.05).
247             Yet, advances directly along the patent-paper boundary are notably more impactful within
248 ; pharmacological properties of published or patented PAR2 modulators (small molecule agonists and an
249 with PfUIS3 can induce a consistent delay in patent parasitemia across mouse strains and against chim
250 s in hydronephrosis and failure to develop a patent pelvic-ureteric junction.
251 trochemical continuous enzyme assay (ICECEA, patent pending) was developed for the fast determination
252                                   During the patent phase of Schistosoma mansoni infection, Foxp3(+)
253 ew innovation bonds, administrative savings, patent pools, and public-private risk sharing collaborat
254     At all time points, the struts along the patent portions of the aneurysm necks harbored scattered
255  occlusion or stenosis and the presence of a patent portosystemic shunt.
256           Researchers can participate in the patent process without sacrificing a robust publishing c
257 mbined with a basic understanding of how the patent process works.
258 nticancer drugs ("chemotherapies") that were patent protected and administered intravenously to patie
259                                              Patent protection for several LMWH has expired and abbre
260 K9i drug price of $14300, with a lapse in US patent protection that would reduce the price by 43% in
261            Drawing on millions of papers and patents published over 30 years, we use this model to in
262 nvoluntary acquisition of the pharmaceutical patents pursuant to federal statutory authority and prin
263      The overall survival time of completely patent PV and incomplete patent PV immediately after TIP
264  time of completely patent PV and incomplete patent PV immediately after TIPS was 57.05 +/- 0.75 vs.
265 omosis was performed in 4 cases of small but patent PV.
266 tion (LRVL) is another option but requires a patent PV.
267 ribute to onward transmission and subsequent patent recrudescence.
268 search, from both scientific literatures and patents, related to the compaction of TMUPS.
269               The unprecedented weakening of patent rights in the United States undermines necessary
270 riptional signature of TET2 mutations in MPN patent samples.
271                                        Fewer patent secondary follicles were isolated from treated ov
272                             Exemplars from a patented series of GPR84 antagonists were able to block
273 ese include reverse payment or pay-for-delay patent settlements, authorized generics, product hopping
274  S. mansoni egg-induced pathology during the patent stage of infection.
275 d documented long-term clinical success with patent stents and no symptoms at one year following inte
276 nce, more particularly CHEMDNER and CHEMDNER patents tasks of BioCreative IV and V, respectively.
277 ormation contained in scientific literature, patents, technical reports, or the web is a pressing nee
278 tically, and show that 'complex' products or patents tend often to be those that countries rarely pro
279 the Bxb1-att nor the Cre-lox system is under patent, there is freedom to operate.
280 as well as SureChEMBL for recent PDE related patents, to provide a wider context for exploring fragme
281  eyes with ischemic nonfunctioning blebs and patent trabeculectomy ostia.
282              Here, we compare the outcome of patents treated within the Veterans Health Administratio
283                            Linked papers and patents typically stand 2 to 4 degrees distant from the
284 "products of nature" were not eligible to be patented unless they were "isolated and purified" from t
285 tion coexisted with other anomalies, such as patent urachus, Meckel's diverticulum, mesenteric cyst,
286  impact on new drug development, as new drug patents usually involve cellular methods.
287            Follow-up ultrasound demonstrated patent vasculature without evidence of thrombosis or out
288 ion is suppressed and maintains a quiescent, patent vasculature.
289 rmed 24 hours after the procedure revealed a patent vessel with satisfactory blood flow.
290                         Imaging demonstrated patent vessels with only mild luminal narrowing/occlusio
291 he ablation zone, largely along persistently patent vessels.
292 ad a history of liver toxic drug absorption, patent viral infection, or any histopathological finding
293        The excluded aneurysm sac shrank with patent visceral branches and there was an absence of end
294                                 Isolated DNA patents were already becoming obsolete on scientific gro
295 logical assessment, revealed both BRSs to be patent with nonobstructive neointimal hyperplasia.
296  culprit vessel may be preserved in selected patents with NSTEMI.
297 ization is essential to optimize outcomes in patents with ST-segment-elevation myocardial infarction
298 in K antagonist (VKA) in atrial fibrillation patents with stable coronary artery disease.
299 raphy at 1 month showed that all shunts were patent, with no thrombosis or migration.
300  609 (26.7%), of which 150 (92%) occurred in patents without antecedent CMV viremia.

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top